Compare Stocks: TNXP, TECX, PROK, and AVTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$15.13 +1.8%	$17.80	$89.95 ▼ $99.05	$438.54M	0.95	53,591 shs	932,727 shs
PROK ProKidney	$1.43 -0.7%	$1.67	$1.30 ▼ $3.48	$432.32M	1.77	1.11 million shs	584,219 shs
TECX Tectonic Therapeutic	$21.09 -3.4%	$28.03	$15.52 ▼ $39.53	$412.31M	3.28	259,493 shs	251,376 shs
TNXP Tonix Pharmaceuticals	$5.13 -5.5%	$10.58	$5.05 ▼ $20.58	$87.99M	1.78	515,251 shs	899,299 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+7.45%	+10.73%	-12.28%	-25.14%	+48.60%
PROK ProKidney	0.00%	-2.04%	-18.87%	-5.26%	-56.36%
TECX Tectonic Therapeutic	+0.05%	+4.20%	-17.99%	-30.91%	+15.01%
TNXP Tonix Pharmaceuticals	-6.06%	-15.16%	-49.35%	-48.87%	-72.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$15.13 +1.8%	$17.80	$89.95 ▼ $99.05	$438.54M	0.95	53,591 shs	932,727 shs
PROK ProKidney	$1.43 -0.7%	$1.67	$1.30 ▼ $3.48	$432.32M	1.77	1.11 million shs	584,219 shs
TECX Tectonic Therapeutic	$21.09 -3.4%	$28.03	$15.52 ▼ $39.53	$412.31M	3.28	259,493 shs	251,376 shs
TNXP Tonix Pharmaceuticals	$5.13 -5.5%	$10.58	$5.05 ▼ $20.58	$87.99M	1.78	515,251 shs	899,299 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	+7.45%	+10.73%	-12.28%	-25.14%	+48.60%
PROK ProKidney	0.00%	-2.04%	-18.87%	-5.26%	-56.36%
TECX Tectonic Therapeutic	+0.05%	+4.20%	-17.99%	-30.91%	+15.01%
TNXP Tonix Pharmaceuticals	-6.06%	-15.16%	-49.35%	-48.87%	-72.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
PROK ProKidney	2.67	Moderate Buy	$12.00	740.34% Upside
TECX Tectonic Therapeutic	2.80	Moderate Buy	$69.17	228.99% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	378.05% Upside

Current Analyst Ratings Breakdown

Latest TNXP, TECX, PROK, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy
10/15/2026	TECX Tectonic Therapeutic	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/11/2026	TECX Tectonic Therapeutic	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral	$26.00
10/11/2026	TECX Tectonic Therapeutic	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/6/2026	PROK ProKidney	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/30/2026	TECX Tectonic Therapeutic	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$80.00
9/30/2026	TECX Tectonic Therapeutic	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/1/2026	TECX Tectonic Therapeutic	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
8/18/2026	TECX Tectonic Therapeutic	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy	$27.00
8/7/2026	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$101.00 ➝ $93.00

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
PROK ProKidney	$818K	527.77	N/A	N/A	($3.36) per share	-0.43
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$13.43 per share	N/A
TNXP Tonix Pharmaceuticals	$29.10M	3.02	N/A	N/A	$19.17 per share	0.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	N/A
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)
TECX Tectonic Therapeutic	-$74.15M	-$4.57	N/A	N/A	N/A	N/A	-35.26%	-33.59%	11/5/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest TNXP, TECX, PROK, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	PROK ProKidney	-$0.13	N/A	N/A	N/A	$0.13 million	N/A
11/9/2026	Q3 2026	TNXP Tonix Pharmaceuticals	-$2.52	N/A	N/A	N/A	$16.00 million	N/A
11/5/2026	Q3 2026	TECX Tectonic Therapeutic	-$1.3163	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million
8/6/2026	Q2 2026	TECX Tectonic Therapeutic	-$1.35	-$1.18	+$0.17	-$1.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
PROK ProKidney	N/A	8.36	8.36
TECX Tectonic Therapeutic	N/A	22.29	22.29
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
PROK ProKidney	51.59%
TECX Tectonic Therapeutic	62.63%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
PROK ProKidney	39.83%
TECX Tectonic Therapeutic	39.80%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
PROK ProKidney	231	302.32 million	181.91 million	Optionable
TECX Tectonic Therapeutic	60	19.55 million	11.77 million	Optionable
TNXP Tonix Pharmaceuticals	142	17.15 million	16.81 million	Optionable

TNXP, TECX, PROK, and AVTE Headlines

Recent News About These Companies

A New Fibromyalgia Drug Deal Reaches 21 Million More Medicare Lives. Her Own Plan Could Still Decide What She Pays

October 22 at 8:04 AM | 247wallst.com

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain

October 19 at 10:06 AM | finance.yahoo.com

Tonix Pharmaceuticals Sets 2027 Phase 1 Target For TNX-801 Vaccine Candidate

October 15, 2026 | rttnews.com

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

October 15, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026

October 15, 2026 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) vs. SAB Biotherapeutics (NASDAQ:SABS) Head to Head Review

October 12, 2026 | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Raised to "Hold" at Wall Street Zen

October 4, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell

September 26, 2026 | marketbeat.com

Tonix Pharmaceuticals Holding Corp (TNXP)

September 23, 2026 | in.investing.com

InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA(R) Medicare Coverage to 32 Million Lives

September 22, 2026 | financialcontent.comF

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

September 22, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

September 22, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)

September 16, 2026 | theglobeandmail.com

Tonix Pharmaceuticals Holding Corp. (TNXP)

September 15, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Tyra Bioscience (TYRA) and Becton Dickinson (BDX)

September 9, 2026 | theglobeandmail.com

Tonix Names Englese Chief Commercial Officer To Expand TONMYA Reach

September 9, 2026 | rttnews.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | finance.yahoo.com

Tonix Pharma Appoints New Chief Commercial Officer

September 8, 2026 | tipranks.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | globenewswire.com

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

September 2, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

September 2, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, TECX, PROK, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$15.13 +0.27 (+1.82%)

As of 10/21/2026

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

ProKidney NASDAQ:PROK

$1.43 -0.01 (-0.69%)

Closing price 04:00 PM Eastern

Extended Trading

$1.42 0.00 (-0.35%)

As of 05:02 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tectonic Therapeutic NASDAQ:TECX

$21.09 -0.75 (-3.43%)

Closing price 04:00 PM Eastern

Extended Trading

$20.67 -0.42 (-2.01%)

As of 04:25 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Tonix Pharmaceuticals NASDAQ:TNXP

$5.13 -0.30 (-5.52%)

Closing price 04:00 PM Eastern

Extended Trading

$5.16 +0.03 (+0.64%)

As of 05:01 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, TECX, PROK, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, TECX, PROK, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, TECX, PROK, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, TECX, PROK, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

ProKidney NASDAQ:PROK

Tectonic Therapeutic NASDAQ:TECX

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TNXP, TECX, PROK, and AVTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TNXP, TECX, PROK, and AVTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TNXP, TECX, PROK, and AVTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, TECX, PROK, and AVTE Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

ProKidney NASDAQ:PROK

Tectonic Therapeutic NASDAQ:TECX

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools